Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo
- PMID: 25904740
- DOI: 10.1126/scitranslmed.aaa1983
Monoclonal antibodies against GARP/TGF-β1 complexes inhibit the immunosuppressive activity of human regulatory T cells in vivo
Abstract
Regulatory T cells (Tregs) are essential to prevent autoimmunity, but excessive Treg function contributes to cancer progression by inhibiting antitumor immune responses. Tregs exert contact-dependent inhibition of immune cells through the production of active transforming growth factor-β1 (TGF-β1). On the Treg cell surface, TGF-β1 is in an inactive form bound to membrane protein GARP and then activated by an unknown mechanism. We demonstrate that GARP is involved in this activation mechanism. Two anti-GARP monoclonal antibodies were generated that block the production of active TGF-β1 by human Tregs. These antibodies recognize a conformational epitope that requires amino acids GARP137-139 within GARP/TGF-β1 complexes. A variety of antibodies recognizing other GARP epitopes did not block active TGF-β1 production by Tregs. In a model of xenogeneic graft-versus-host disease in NSG mice, the blocking antibodies inhibited the immunosuppressive activity of human Tregs. These antibodies may serve as therapeutic tools to boost immune responses to infection or cancer via a mechanism of action distinct from that of currently available immunomodulatory antibodies. Used alone or in combination with tumor vaccines or antibodies targeting the CTLA4 or PD1/PD-L1 pathways, blocking anti-GARP antibodies may improve the efficiency of cancer immunotherapy.
Copyright © 2015, American Association for the Advancement of Science.
Comment in
-
Reigning in regulatory T-cell function.Nat Biotechnol. 2015 Jul;33(7):718-9. doi: 10.1038/nbt.3285. Nat Biotechnol. 2015. PMID: 26154011 No abstract available.
Similar articles
-
Blocking immunosuppression by human Tregs in vivo with antibodies targeting integrin αVβ8.Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):E10161-E10168. doi: 10.1073/pnas.1710680114. Epub 2017 Nov 6. Proc Natl Acad Sci U S A. 2017. PMID: 29109269 Free PMC article.
-
Suppression of lysosome metabolism-meditated GARP/TGF-β1 complexes specifically depletes regulatory T cells to inhibit breast cancer metastasis.Oncogene. 2024 Jun;43(25):1930-1940. doi: 10.1038/s41388-024-03043-y. Epub 2024 May 2. Oncogene. 2024. PMID: 38698265
-
Blocking GARP-mediated activation of TGF-β1 did not alter innate or adaptive immune responses to bacterial infection or protein immunization in mice.Cancer Immunol Immunother. 2022 Aug;71(8):1851-1862. doi: 10.1007/s00262-021-03119-8. Epub 2022 Jan 1. Cancer Immunol Immunother. 2022. PMID: 34973084 Free PMC article.
-
Garp as a therapeutic target for modulation of T regulatory cell function.Expert Opin Ther Targets. 2017 Feb;21(2):191-200. doi: 10.1080/14728222.2017.1275568. Epub 2016 Dec 29. Expert Opin Ther Targets. 2017. PMID: 28001437 Review.
-
GARP: a surface molecule of regulatory T cells that is involved in the regulatory function and TGF-β releasing.Oncotarget. 2016 Jul 5;7(27):42826-42836. doi: 10.18632/oncotarget.8753. Oncotarget. 2016. PMID: 27095576 Free PMC article. Review.
Cited by
-
Therapeutic activity of GARP:TGF-β1 blockade in murine primary myelofibrosis.Blood. 2023 Feb 2;141(5):490-502. doi: 10.1182/blood.2022017097. Blood. 2023. PMID: 36322928 Free PMC article.
-
The GARP/Latent TGF-β1 complex on Treg cells modulates the induction of peripherally derived Treg cells during oral tolerance.Eur J Immunol. 2016 Jun;46(6):1480-9. doi: 10.1002/eji.201546204. Epub 2016 Apr 23. Eur J Immunol. 2016. PMID: 27062243 Free PMC article.
-
Immuno-oncology moves beyond PD-1.Nat Biotechnol. 2015 Jul;33(7):673-5. doi: 10.1038/nbt0715-673. Nat Biotechnol. 2015. PMID: 26153987 No abstract available.
-
Regulatory T Cell-Derived TGF-β1 Controls Multiple Checkpoints Governing Allergy and Autoimmunity.Immunity. 2020 Dec 15;53(6):1202-1214.e6. doi: 10.1016/j.immuni.2020.10.002. Epub 2020 Oct 20. Immunity. 2020. PMID: 33086036 Free PMC article.
-
Comparison of Mesenchymal Stromal Cells From Different Origins for the Treatment of Graft-vs.-Host-Disease in a Humanized Mouse Model.Front Immunol. 2019 Apr 2;10:619. doi: 10.3389/fimmu.2019.00619. eCollection 2019. Front Immunol. 2019. PMID: 31001253 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials
Miscellaneous